3Preiss D, Seshasai SRK, Welsh P, et al. Risk of incident diabe- tes with intensive-dose compared with moderate-dose statin thera- py: a meta-analysis[ J]. JAMA, 2011, 305(24):2556-2564.
4Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins [ J ]. Lancet, 2005, 366(9493) :1267-1278.
5Kearney PM, BlackweU L, Collins R, et al. Efficacy of choles- terol-lowering therapy in 18 686 people with diabetes in 14 ran- domised trims of statins : a meta-analysis [ J ]. Lancet, 2008, 371 (9607) :117-125.
7Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study : a post-hoc analysis [ J ]. Lancet, 2010, 376 ( 9756 ) : 1916-1922.
8USA FDA. FDA expand advice on statin risks[ EB/OL] (2011- 04-11 ) [ 2012-03-04 ]. http ://www. fda. gov/Drugs/DrugSafety/ ucm293101.
9Sattar N, Preiss D, Murray HM, et al. Statins and risk of inci- dent diabetes: a collaborative meta-analysis of randomised statin trials[J]. Lancet, 2010, 375(9716) :735-742.
10Rajpathak SN, Kumbhani DJ, Crandall J, et al. Statin therapy and risk of developing type 2 diabetes: a meta-analysis [ J ]. Dia- betes Care, 2009, 32(10) : 1924-1929.
